Maravai LifeSciences unit TriLink wins new China CleanCap patent for cap analog compounds

By Public Technologies
  • Maravai LifeSciences’ TriLink BioTechnologies won a new China patent covering CleanCap cap analog compounds used to make 5’-capped RNAs.
  • Protection extends to RNAs containing the compounds, cells containing those RNAs, drug products, and other pharmaceutical compositions.
  • The grant follows a separate China patent issued months earlier covering methods for synthesizing capped RNA, strengthening regional IP coverage.
  • CleanCap is used in commercially approved COVID-19 mRNA and saRNA vaccines, supporting licensing and supply-chain control in China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260929862025) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.